Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has ...

A 2026 informational overview of how Purisaki Deep Cleansing Foot Pads are described in company materials — including the 2-in-1 detoxification and vitamin infusion positioning, ingredient research ...

An informational report compiling GaraHerb's publicly available product materials, ingredient-level research references, formulation transparency considerations, and consumer details for 2026 Aurora, ...

Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, ...

GLP-1 telehealth platforms, including how commonly searched topics such as "claims evaluated" and "safety risks assessed" relate to publicly available company information, FDA communications, and ...

An informational report based on materials provided by MetaFit Pharma Solutions LLC detailing how the TrimRx telehealth platform presents its GLP-1 medication options, compounded and FDA-approved ...

Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment. TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, ...

An informational report outlining how Akemi Detox Tea is presented in official materials, including ingredient research context, metabolic support positioning, and consumer considerations Elizabeth, ...

On 19 March 2026, Fagron received a transparency notification from Aberdeen Group plc, informing the Company that its shareholding has crossed the lowest 3% disclosure threshold downwards, following a ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an ePoster ...

XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares, ...